 |
Ability Pharmaceuticals |
ABTL0812 |
Biodrugs/ Drugs |
Cancer |
Lung, Endometrial and Pancreatic Cancer |
4PhII |
España, EEUU, Francia e Israel |
ABTL0812
Therapeutic area:
Cancer
|
 |
Accure Therapeutics |
ACT-01 |
Biodrugs/ Drugs |
Central Nervous System
Ophthalmology and optometry |
Acute Optic Neuritis, Neuromyelitis Optica, Multiple Sclerosis |
3PhI |
|
ACT-01
Therapeutic area:
Central Nervous System
Ophthalmology and optometry
|
 |
Allinky Biopharma |
AIK3 |
Biodrugs/ Drugs |
Autoimmune & Inflammation
Metabolic / Endocrinology |
Idiopathic Pulmonary Fibrosis (IPF), Non-Alcoholic Steatohepatitis (NASH), autoinflammatory diseases, osteoarthritis, gout, etc... |
2RP |
Spain, France, USA, India |
AIK3
Therapeutic area:
Autoimmune & Inflammation
Metabolic / Endocrinology
|
 |
Almirall |
Efinaconazole |
Biodrugs/ Drugs |
Dermatology
Infections |
Onychomicosis |
6Reg. |
EU |
Efinaconazole
Therapeutic area:
Dermatology
Infections
|
|
Almirall |
Lebrikizumab |
Biodrugs/ Drugs |
Dermatology |
Atopic Dermatitis |
6Reg. |
EU (incluida España) |
Lebrikizumab
Therapeutic area:
Dermatology
|
|
Almirall |
IL-2 mu Fc |
Biodrugs/ Drugs |
Dermatology |
Autoimmune dermatology |
2RP |
USA, EU (incluida España) |
IL-2 mu Fc
Therapeutic area:
Dermatology
|
|
Almirall |
Anti-IL-1RAP mAb |
Biodrugs/ Drugs |
Dermatology |
Autoimmune dermatology |
3PhI |
USA, España (algunos estudios preclínicos) |
Anti-IL-1RAP mAb
Therapeutic area:
Dermatology
|
|
Almirall |
Tirbanibulin (extended label) |
Biodrugs/ Drugs |
Dermatology |
Actinic keratosis |
5PhIII |
USA, EU (incluida España) |
Tirbanibulin (extended label)
Therapeutic area:
Dermatology
|
 |
Aptatargets |
APTOLL-02 |
Biodrugs/ Drugs |
Autoimmune & Inflammation
Infections
Respiratory and Pulmonary system |
COVID-19, Acute Respiratory Distress Syndrome (ARDS) |
3PhI |
Spain |
APTOLL-02
Therapeutic area:
Autoimmune & Inflammation
Infections
Respiratory and Pulmonary system
|
|
Aptatargets |
APTOLL-01 |
Biodrugs/ Drugs |
Autoimmune & Inflammation
Cardiovascular and circulatory systems |
Acute Myocardial Infarction |
2RP |
|
APTOLL-01
Therapeutic area:
Autoimmune & Inflammation
Cardiovascular and circulatory systems
|
|
Aptatargets |
APTOLL-02 |
Biodrugs/ Drugs |
Autoimmune & Inflammation
Cardiovascular and circulatory systems
Central Nervous System |
Multiple Sclerosis |
2RP |
|
APTOLL-02
Therapeutic area:
Autoimmune & Inflammation
Cardiovascular and circulatory systems
Central Nervous System
|
|
Aptatargets |
APTOLL-01 |
Biodrugs/ Drugs |
Autoimmune & Inflammation
Cardiovascular and circulatory systems
Central Nervous System |
Acute Ischemic Stroke |
4PhII |
Spain, France, Germany |
APTOLL-01
Therapeutic area:
Autoimmune & Inflammation
Cardiovascular and circulatory systems
Central Nervous System
|
 |
APTUS Biotech |
AptaMnkQ2 |
Biodrugs/ Drugs |
Cancer
Womens health |
ApMNKQ2 is a 29-nucleotide aptamer targeting kinase MNK1b that have shown capable of reducing tumor size, inhibiting tumor cell proliferation and inducing apoptosis in an orthotopic model of triple-negative breast cancer. |
1NRP |
|
AptaMnkQ2
Therapeutic area:
Cancer
Womens health
|
|
APTUS Biotech |
CAT-ApMnkQ2 |
Biodrugs/ Drugs |
Cancer |
Aptusbiotech intend to develop novel therapies against Anaplastic Thyroid Cancer (CAT) based on our aptamer apMNKQ2 improving its design and applying updated formulations |
1NRP |
|
CAT-ApMnkQ2
Therapeutic area:
Cancer
|
 |
Araclon Biotech |
ABvac40 |
Vaccines |
Central Nervous System |
Alzheimer's Disease |
4PhII |
Spain, France, Italia, Sweeden |
ABvac40
Therapeutic area:
Central Nervous System
|
 |
Archivel Farma |
RUTI |
Biodrugs/ Drugs |
Cancer |
Non-muscle Invasive Bladder Cancer (NMIBC) |
3PhI |
Spain |
RUTI
Therapeutic area:
Cancer
|
|
Archivel Farma |
RUTI |
Vaccines |
Infections |
Drug Susceptible (DS)- Tuberculosis (TB)
Drug Resistance (DR)- TB
Latent TB infection (LTBI) |
4PhII |
Ukraine, India, Argentina, Spain and Southafrica |
RUTI
Therapeutic area:
Infections
|
 |
Arthex Biotech |
Anti-miRNA |
Biodrugs/ Drugs |
Musculoskeletal Disorders |
Osteoarthritis |
1NRP |
spain |
Anti-miRNA
Therapeutic area:
Musculoskeletal Disorders
|
|
Arthex Biotech |
ARTHEx-01 |
Biodrugs/ Drugs |
Genetic Diseases and Dysmorphic syndromes
Musculoskeletal Disorders |
Myotonic dystrophy type 1 (DM1) |
2RP |
Spain, UK, France, Germany |
ARTHEx-01
Therapeutic area:
Genetic Diseases and Dysmorphic syndromes
Musculoskeletal Disorders
|
 |
ATRYS HEALTH |
NILO1 |
Biodrugs/ Drugs |
Cancer
Central Nervous System |
Brain tumor and brain lesions |
1NRP |
Spain |
NILO1
Therapeutic area:
Cancer
Central Nervous System
|
 |
CIBER |
MicroRNA for the treatment of obesity |
Gene / Cell Therapy |
Metabolic / Endocrinology |
Obesity treatment |
1NRP |
|
MicroRNA for the treatment of obesity
Therapeutic area:
Metabolic / Endocrinology
|
|
CIBER |
APTAMERS FOR THE TREATMENT OF CONGENITAL AND ACQUIRED NEUTROPENIAS |
Biodrugs/ Drugs |
Cancer
Genetic Diseases and Dysmorphic syndromes
Others |
Aptamers for the treatment of congenital and acquired Neutropenias |
1NRP |
Spain |
APTAMERS FOR THE TREATMENT OF CONGENITAL AND ACQUIRED NEUTROPENIAS
Therapeutic area:
Cancer
Genetic Diseases and Dysmorphic syndromes
Others
|
|
CIBER |
COMPOSITIONS AND METHODS FOR TREATING METABOLIC DISORDERS |
Biodrugs/ Drugs |
Metabolic / Endocrinology |
obesity-related metabolic disorders, obesity-related tissue dysfunction |
1NRP |
|
COMPOSITIONS AND METHODS FOR TREATING METABOLIC DISORDERS
Therapeutic area:
Metabolic / Endocrinology
|
|
CIBER |
GENETICALLY MODIFIED MSCs overexpressing CXCR4-IL10 AS ALTERNATIVE TREATMENT FOR GRAFT versus HOST DISEASE |
Gene / Cell Therapy |
Autoimmune & Inflammation |
GRAFT versus HOST DISEASE |
2RP |
Spain |
GENETICALLY MODIFIED MSCs overexpressing CXCR4-IL10 AS ALTERNATIVE TREATMENT FOR GRAFT versus HOST DISEASE
Therapeutic area:
Autoimmune & Inflammation
|
|
CIBER |
Pharmaceutical and nutraceutical compositions with a combination of amino acids and its use in diseases characterized by lipid accumulation in tissues |
Biodrugs/ Drugs |
Cardiovascular and circulatory systems
Kidney and Genitourinary system
Metabolic / Endocrinology |
Obesity, atherosclerosis |
2RP |
|
Pharmaceutical and nutraceutical compositions with a combination of amino acids and its use in diseases characterized by lipid accumulation in tissues
Therapeutic area:
Cardiovascular and circulatory systems
Kidney and Genitourinary system
Metabolic / Endocrinology
|
|
CIBER |
DREAM NEURONAL CALCIUM SENSOR-MODULATING COMPOUNDS, AND THERAPEUTIC USES THEREOF |
Biodrugs/ Drugs |
Central Nervous System |
CSIC, CIBERNED and UAM – Modulators of the neuronal calcium sensor DREAM (Downstream Regulator Element antagonist modulator). These compounds may be useful in pathologies associated for Huntington’s disease treatment |
1NRP |
Spain |
DREAM NEURONAL CALCIUM SENSOR-MODULATING COMPOUNDS, AND THERAPEUTIC USES THEREOF
Therapeutic area:
Central Nervous System
|
|
CIBER |
Pharmaceutical composition comprising 5-dodecanolide, its preparation and its use |
Biodrugs/ Drugs |
Autoimmune & Inflammation |
anti-inflammatory diseases |
1NRP |
|
Pharmaceutical composition comprising 5-dodecanolide, its preparation and its use
Therapeutic area:
Autoimmune & Inflammation
|
|
CIBER |
GUT MICROBIOTA COMPOSITION FOR THE PREVENTION AND/OR TREATMENT OF A MENTAL DISORDER |
Biodrugs/ Drugs |
Others |
The present invention is a gut microbiota composition comprising a wide range of species of genus with a vast array of applications for use in the specific prevention and/or treatment of a mental disorder with memory impairment in a subject. |
1NRP |
Spain |
GUT MICROBIOTA COMPOSITION FOR THE PREVENTION AND/OR TREATMENT OF A MENTAL DISORDER
Therapeutic area:
Others
|
|
CIBER |
BACTERIOPHAGUE FOR THE PREVENTION AND TREATMENT OF A MENTAL DISORDERS |
Biodrugs/ Drugs |
Central Nervous System |
Mental health |
2RP |
|
BACTERIOPHAGUE FOR THE PREVENTION AND TREATMENT OF A MENTAL DISORDERS
Therapeutic area:
Central Nervous System
|
|
CIBER |
Pharmaceutical composition for use in the treatment of depression by the intranasal via |
Biodrugs/ Drugs |
Central Nervous System |
Treatment for depression |
1NRP |
|
Pharmaceutical composition for use in the treatment of depression by the intranasal via
Therapeutic area:
Central Nervous System
|
|
CIBER |
Method for precise gene editing of the COL7A1 gene by homologous recombination-based editing |
Gene / Cell Therapy |
Dermatology |
Epidermolysis Bullosa |
1NRP |
Spain |
Method for precise gene editing of the COL7A1 gene by homologous recombination-based editing
Therapeutic area:
Dermatology
|
|
CIBER |
CARVACROL AS DISINFECTANT AGAINST LEGIONELLA |
Biodrugs/ Drugs |
Infections
Others |
Legionella |
1NRP |
|
CARVACROL AS DISINFECTANT AGAINST LEGIONELLA
Therapeutic area:
Infections
Others
|
|
CIBER |
Gene Therapy for the treatment of Diamond-Blackfan Anemia |
Gene / Cell Therapy |
Blood and Lymphatic systems
Genetic Diseases and Dysmorphic syndromes |
Diamond-Blackfan Anemia |
2RP |
Europe |
Gene Therapy for the treatment of Diamond-Blackfan Anemia
Therapeutic area:
Blood and Lymphatic systems
Genetic Diseases and Dysmorphic syndromes
|
|
CIBER |
Gene editing medicinal product for Epidermolysis Bullosa |
Gene / Cell Therapy |
Dermatology |
Epidermolysis Bullosa. Autologous skin equivalent graft composed of keratinocytes and fibroblasts genetically corrected by Crispr/Cas9-mediated |
2RP |
Spain |
Gene editing medicinal product for Epidermolysis Bullosa
Therapeutic area:
Dermatology
|
|
CIBER |
Pharmaceutical compositions for the prevention of Charcot-Marie-Tooth disease |
Biodrugs/ Drugs |
Central Nervous System |
Charcot-Marie-Tooth disease. |
1NRP |
Spain |
Pharmaceutical compositions for the prevention of Charcot-Marie-Tooth disease
Therapeutic area:
Central Nervous System
|
|
CIBER |
Combined use of biotine and thiamine for prevention and treatment of Hungtington Disease |
Biodrugs/ Drugs |
Central Nervous System |
CSIC and the CIBERNED have determined that the combined administration of biotin and thiamine is capable of improving motor symptoms and reducing striatal atrophy associated with Huntington Disease (HD). |
1NRP |
Spain |
Combined use of biotine and thiamine for prevention and treatment of Hungtington Disease
Therapeutic area:
Central Nervous System
|
|
CIBER |
COMPOUNDS FOR TREATING HELICOBACTER PYLORI AND CAMPYLOBACTER JEJUNI INFECTION |
Biodrugs/ Drugs |
Digestive System
Infections |
The present invention describes new bioactive compounds with antimicrobial activity against Helicobacter pylori (H. pylori) and Campylobacter jejuni (C. jejuni) by acting specifically on the protein HsrA (essential for cell viability). |
1NRP |
Spain |
COMPOUNDS FOR TREATING HELICOBACTER PYLORI AND CAMPYLOBACTER JEJUNI INFECTION
Therapeutic area:
Digestive System
Infections
|
|
CIBER |
GENE EDITING FOR THE TREATMENT OF EWING’S SARCOMA |
Gene / Cell Therapy |
Cancer |
EWING’S SARCOMA |
1NRP |
Spain |
GENE EDITING FOR THE TREATMENT OF EWING’S SARCOMA
Therapeutic area:
Cancer
|
 |
DIOMUNE SL |
IV1303 |
Biodrugs/ Drugs |
Autoimmune & Inflammation
Cardiovascular and circulatory systems
Genetic Diseases and Dysmorphic syndromes
Infections |
Sepsis treatment, Stroke, Rare diseases (CDH), Leishmania, ZIKV |
2RP |
|
IV1303
Therapeutic area:
Autoimmune & Inflammation
Cardiovascular and circulatory systems
Genetic Diseases and Dysmorphic syndromes
Infections
|
 |
Dobecure |
Ethamsylate |
Biodrugs/ Drugs |
Blood and Lymphatic systems
Genetic Diseases and Dysmorphic syndromes |
Rendu-Osler-Weber syndrome or Hereditary Hemorrhagic Telangiectasia (HHT) |
5PhIII |
Spain |
Ethamsylate
Therapeutic area:
Blood and Lymphatic systems
Genetic Diseases and Dysmorphic syndromes
|
|
Dobecure |
Ethamsylate |
Biodrugs/ Drugs |
Ophthalmology and optometry |
Dry Age-Related Macular Degeneration |
6Reg. |
EU level - Spain, Italy, Portugal |
Ethamsylate
Therapeutic area:
Ophthalmology and optometry
|
 |
FERRER |
FNP-122 |
Biodrugs/ Drugs |
Central Nervous System |
Neuromotor disorders |
5PhIII |
|
FNP-122
Therapeutic area:
Central Nervous System
|
|
FERRER |
FNP-117 |
Gene / Cell Therapy |
Central Nervous System |
Spinal Cord Injury |
4PhII |
|
FNP-117
Therapeutic area:
Central Nervous System
|
|
FERRER |
FNP-150 |
Biodrugs/ Drugs |
Central Nervous System |
Parkinson |
4PhII |
|
FNP-150
Therapeutic area:
Central Nervous System
|
|
FERRER |
FNP-120 |
Biodrugs/ Drugs |
Ophthalmology and optometry |
Diabetic Retinopathy |
4PhII |
|
FNP-120
Therapeutic area:
Ophthalmology and optometry
|
|
FERRER |
FNP-202 |
Biodrugs/ Drugs |
Respiratory and Pulmonary system |
Pulmonary Arterial Hypertension |
5PhIII |
|
FNP-202
Therapeutic area:
Respiratory and Pulmonary system
|
|
FERRER |
FNP-911 |
Biodrugs/ Drugs |
Analgesia & Pain |
Osteoarthritis |
1NRP |
|
FNP-911
Therapeutic area:
Analgesia & Pain
|
|
FERRER |
FNP-010 |
Biodrugs/ Drugs |
Central Nervous System |
Cyclic Vomiting Syndrome |
4PhII |
|
FNP-010
Therapeutic area:
Central Nervous System
|
|
FERRER |
FNP-080 |
Biodrugs/ Drugs |
Cardiovascular and circulatory systems |
Secondary prevention of cardiovascular accidents |
3PhI |
|
FNP-080
Therapeutic area:
Cardiovascular and circulatory systems
|
 |
FUND. PROGRESO Y SALUD |
FIBICO-14003 LISED OF MESENCHYMAL STEM CELLS FOR THE TREATMENT OF MUSCULAR SKELETAL INJURIES |
Gene / Cell Therapy |
Musculoskeletal Disorders |
Musculoskeletal disorders |
1NRP |
|
FIBICO-14003 LISED OF MESENCHYMAL STEM CELLS FOR THE TREATMENT OF MUSCULAR SKELETAL INJURIES
Therapeutic area:
Musculoskeletal Disorders
|
|
FUND. PROGRESO Y SALUD |
CABIMER- 21001 Use of melatonin to improve the therapeutic potential of mesenchymal stem cells in cancer |
Biodrugs/ Drugs |
Cancer |
Cancer |
1NRP |
|
CABIMER- 21001 Use of melatonin to improve the therapeutic potential of mesenchymal stem cells in cancer
Therapeutic area:
Cancer
|
|
FUND. PROGRESO Y SALUD |
FISEVI-13002 CANNABIOTICS |
Biodrugs/ Drugs |
Cancer |
Multiple myeloma |
2RP |
|
FISEVI-13002 CANNABIOTICS
Therapeutic area:
Cancer
|
|
FUND. PROGRESO Y SALUD |
GENYO-20001 CRISPNA, A NEW TOOL FOR GENOME EDITING AND DIAGNOSIS |
Gene / Cell Therapy |
Others |
Genome Editing and Diagnosis |
1NRP |
|
GENYO-20001 CRISPNA, A NEW TOOL FOR GENOME EDITING AND DIAGNOSIS
Therapeutic area:
Others
|
|
FUND. PROGRESO Y SALUD |
CABIMER-19002 NON-VIRAL VECTORS FROM MESOPOROUS NANOPARTICLES FOR THEIR APPLICATION IN GENE THERAPY FOR THE TREATMENT OF DEGENERATIVE DISEASES OF THE RETINA |
Gene / Cell Therapy |
Ophthalmology and optometry |
Degenerative diseases of the retina |
1NRP |
|
CABIMER-19002 NON-VIRAL VECTORS FROM MESOPOROUS NANOPARTICLES FOR THEIR APPLICATION IN GENE THERAPY FOR THE TREATMENT OF DEGENERATIVE DISEASES OF THE RETINA
Therapeutic area:
Ophthalmology and optometry
|
 |
FUNDACIÓN JIMÉNEZ DÍAZ (Instituto de Investigación Sanitaria) |
Treatment of epidermolysis bullosa |
Gene / Cell Therapy |
Genetic Diseases and Dysmorphic syndromes |
Genome editing in primary keratinocytes for Epidermolysis bullosa treatment |
3PhI |
Spain |
Treatment of epidermolysis bullosa
Therapeutic area:
Genetic Diseases and Dysmorphic syndromes
|
|
FUNDACIÓN JIMÉNEZ DÍAZ (Instituto de Investigación Sanitaria) |
Pyruvate kinase deficiency (PKD) |
Gene / Cell Therapy |
Blood and Lymphatic systems
Genetic Diseases and Dysmorphic syndromes |
Pyruvate kinase deficiency gene editing treatment method |
3PhI |
Spain |
Pyruvate kinase deficiency (PKD)
Therapeutic area:
Blood and Lymphatic systems
Genetic Diseases and Dysmorphic syndromes
|
|
FUNDACIÓN JIMÉNEZ DÍAZ (Instituto de Investigación Sanitaria) |
Lentiviral vector |
Gene / Cell Therapy |
Genetic Diseases and Dysmorphic syndromes |
In vivo lentiviral gene therapy for the treatment of primary hyperoxaluria type 1 |
2RP |
Spain |
Lentiviral vector
Therapeutic area:
Genetic Diseases and Dysmorphic syndromes
|
|
FUNDACIÓN JIMÉNEZ DÍAZ (Instituto de Investigación Sanitaria) |
Hematopoietic stem cell transplantation (HSCT) |
Gene / Cell Therapy |
Blood and Lymphatic systems
Cancer |
Improvements for performing and facilitating the recovery after hematopoietic stem cell transplantation |
3PhI |
Spain |
Hematopoietic stem cell transplantation (HSCT)
Therapeutic area:
Blood and Lymphatic systems
Cancer
|
|
FUNDACIÓN JIMÉNEZ DÍAZ (Instituto de Investigación Sanitaria) |
New genetic- engineering molecules to CKD |
Biodrugs/ Drugs |
Kidney and Genitourinary system |
Therapy in the prevention of premature ageing related to Chronic Kidney Disease |
1NRP |
|
New genetic- engineering molecules to CKD
Therapeutic area:
Kidney and Genitourinary system
|
|
FUNDACIÓN JIMÉNEZ DÍAZ (Instituto de Investigación Sanitaria) |
Chemical Scalpel |
Biodrugs/ Drugs |
Cancer |
Peritoneal carcinomatosis |
2RP |
Spain |
Chemical Scalpel
Therapeutic area:
Cancer
|
|
FUNDACIÓN JIMÉNEZ DÍAZ (Instituto de Investigación Sanitaria) |
New antigenic trigger |
Biodrugs/ Drugs |
Cardiovascular and circulatory systems |
Method for the diagnosis and/or treatment of atherosclerosis |
1NRP |
Spain |
New antigenic trigger
Therapeutic area:
Cardiovascular and circulatory systems
|
 |
Fundacion MEDINA |
MDN-0090 |
Biodrugs/ Drugs |
Cancer |
Pancreatic Cancer |
1NRP |
|
MDN-0090
Therapeutic area:
Cancer
|
|
Fundacion MEDINA |
MDN-005 |
Biodrugs/ Drugs |
Central Nervous System
Musculoskeletal Disorders |
Amyotrophic lateral sclerosis(ALS) |
1NRP |
|
MDN-005
Therapeutic area:
Central Nervous System
Musculoskeletal Disorders
|
|
Fundacion MEDINA |
MDN-088 |
Biodrugs/ Drugs |
Cancer |
Breast, Colon & Lung Cancer |
1NRP |
|
MDN-088
Therapeutic area:
Cancer
|
 |
Highlight Therapeutics |
BO-112 |
Biodrugs/ Drugs |
Cancer |
Solid tumors in patients with liver metastasis from colorectal cancer or gastric/gastro-esophageal junction cancer. Patients with advanced and/or metastatic melanoma. |
4PhII |
|
BO-112
Therapeutic area:
Cancer
|
 |
Histocell |
HR016 |
Biodrugs/ Drugs |
Respiratory and Pulmonary system |
Acute Lung Injury |
4PhII |
|
HR016
Therapeutic area:
Respiratory and Pulmonary system
|
|
Histocell |
HC016 |
Biodrugs/ Drugs |
Central Nervous System |
Acute Spinal Cord Injury |
4PhII |
|
HC016
Therapeutic area:
Central Nervous System
|
|
Histocell |
HR004 |
Biodrugs/ Drugs |
Musculoskeletal Disorders |
Bone Regeneration |
4PhII |
|
HR004
Therapeutic area:
Musculoskeletal Disorders
|
 |
InnoUp Farma |
INP20 |
Biodrugs/ Drugs |
Others |
Peanut Allergy |
3PhI |
Spain |
INP20
Therapeutic area:
Others
|
|
InnoUp Farma |
INP12 |
Biodrugs/ Drugs |
Cancer |
Breast cancer |
3PhI |
Spain |
INP12
Therapeutic area:
Cancer
|
 |
Institut Quimic de Sarrià (IQS) |
Chondro-implant |
Gene / Cell Therapy |
Cardiovascular and circulatory systems |
Bioactive implant for myocardial regeneration, ventricular support and elliptical shape restoration. Acute Cartilage Injure |
1NRP |
|
Chondro-implant
Therapeutic area:
Cardiovascular and circulatory systems
|
|
Institut Quimic de Sarrià (IQS) |
Cardio-implant |
Gene / Cell Therapy |
Cardiovascular and circulatory systems |
PCL (Polycaprolactone), SAP (self-assembling peptide) bioactive and biomimetic scaffolds for cartilage regeneration. Heart infarct |
1NRP |
|
Cardio-implant
Therapeutic area:
Cardiovascular and circulatory systems
|
 |
IRYCIS |
New compound for the treatment of isquemical stroke |
Biodrugs/ Drugs |
Central Nervous System |
Isquemic stroke |
1NRP |
Spain |
New compound for the treatment of isquemical stroke
Therapeutic area:
Central Nervous System
|
|
IRYCIS |
New aptamers for the treatment of stroke |
Biodrugs/ Drugs |
Central Nervous System |
Stroke |
4PhII |
|
New aptamers for the treatment of stroke
Therapeutic area:
Central Nervous System
|
 |
Laminar Pharma |
LAM181 |
Biodrugs/ Drugs |
Central Nervous System |
Spinal Cord Injury, Pain. Global rigths outlicensed to a third party biotech company |
4PhII |
|
LAM181
Therapeutic area:
Central Nervous System
|
|
Laminar Pharma |
LAM561 |
Biodrugs/ Drugs |
Cancer |
Glioma and other solid tumours |
5PhIII |
|
LAM561
Therapeutic area:
Cancer
|
|
Laminar Pharma |
LAMAC2 |
Biodrugs/ Drugs |
Infections |
Respiratory infections |
3PhI |
|
LAMAC2
Therapeutic area:
Infections
|
|
Laminar Pharma |
LAM204A1 |
Biodrugs/ Drugs |
Autoimmune & Inflammation
Cardiovascular and circulatory systems |
Inflammation, Cardiovascular |
1NRP |
|
LAM204A1
Therapeutic area:
Autoimmune & Inflammation
Cardiovascular and circulatory systems
|
|
Laminar Pharma |
LAMPEC11 |
Biodrugs/ Drugs |
Cancer |
Brain cancer |
1NRP |
|
LAMPEC11
Therapeutic area:
Cancer
|
|
Laminar Pharma |
LAM226A1 |
Biodrugs/ Drugs |
Central Nervous System |
Alzheimer's Disease |
2RP |
|
LAM226A1
Therapeutic area:
Central Nervous System
|
|
Laminar Pharma |
LAM30171 |
Biodrugs/ Drugs |
Cancer
Metabolic / Endocrinology |
Metabolic Diseases, cancer |
1NRP |
|
LAM30171
Therapeutic area:
Cancer
Metabolic / Endocrinology
|
|
Laminar Pharma |
LAM205A1 |
Biodrugs/ Drugs |
Cardiovascular and circulatory systems
Central Nervous System
Metabolic / Endocrinology |
Cardiovascular and Metabolic Diseases, CNS, |
1NRP |
|
LAM205A1
Therapeutic area:
Cardiovascular and circulatory systems
Central Nervous System
Metabolic / Endocrinology
|
|
Laminar Pharma |
LAM182 |
Biodrugs/ Drugs |
Cancer |
Pancreas |
4PhII |
|
LAM182
Therapeutic area:
Cancer
|
 |
Leitat |
Anti-S100A4 |
Biodrugs/ Drugs |
Cancer
Metabolic / Endocrinology |
Anti-cancer
Anti-metastasis
Anti-fibrosis |
1NRP |
|
Anti-S100A4
Therapeutic area:
Cancer
Metabolic / Endocrinology
|
|
Leitat |
COVID |
Biodrugs/ Drugs |
Infections |
Neutralizing antibodies |
1NRP |
|
COVID
Therapeutic area:
Infections
|
 |
Leukos Biotech |
LB208 |
Biodrugs/ Drugs |
Cancer |
Specific and selective HTR1B antagonist, providing a antitumoral agent with potential to address current unmet needs in solid tumors such as TNBC, Hepatocellular Carcinoma or Ovarian Cancer, and in hematological malignancies such as AML or MDS. |
2RP |
Spain |
LB208
Therapeutic area:
Cancer
|
 |
LIbera Bio |
LIB111 |
Biodrugs/ Drugs |
Cancer |
Solid tumors expressing mutant KRAS G12D (e.g. lung, colorectal, pancreatic cancer) |
1NRP |
Spain |
LIB111
Therapeutic area:
Cancer
|
|
LIbera Bio |
LIB125 |
Biodrugs/ Drugs |
Cancer |
Solid tumors expressing mutant KRAS G12V (e.g. lung, colorectal, pancreatic cancer) |
1NRP |
Spain |
LIB125
Therapeutic area:
Cancer
|
 |
Minoryx |
MIN-102 (leriglitazone) |
Biodrugs/ Drugs |
Central Nervous System
Metabolic / Endocrinology |
Chronic X-linked Adrenoleukodystrophy (AMN; Adrenomyeloneuropathy) |
6Reg. |
|
MIN-102 (leriglitazone)
Therapeutic area:
Central Nervous System
Metabolic / Endocrinology
|
|
Minoryx |
MIN-102 (leriglitazone) |
Biodrugs/ Drugs |
Central Nervous System
Metabolic / Endocrinology |
Acute X-linked Adrenoleukodystrophy (cALD; cerebral ALD) |
5PhIII |
Spain, Germany, France |
MIN-102 (leriglitazone)
Therapeutic area:
Central Nervous System
Metabolic / Endocrinology
|
|
Minoryx |
MIN-102 (leriglitazone) |
Biodrugs/ Drugs |
Central Nervous System |
Friedreich's Ataxia |
4PhII |
|
MIN-102 (leriglitazone)
Therapeutic area:
Central Nervous System
|
 |
Neurofix |
NFX91 |
Biodrugs/ Drugs |
Others |
Sleep disorders |
1NRP |
|
NFX91
Therapeutic area:
Others
|
|
Neurofix |
NFX81 |
Biodrugs/ Drugs |
Central Nervous System |
Spinal Cord Injuries |
2RP |
Spain |
NFX81
Therapeutic area:
Central Nervous System
|
|
Neurofix |
NFX88 |
Biodrugs/ Drugs |
Analgesia & Pain
Central Nervous System |
Neuropathic pain |
4PhII |
Spain |
NFX88
Therapeutic area:
Analgesia & Pain
Central Nervous System
|
 |
Oniria Therapeutics |
ONR-001 |
Biodrugs/ Drugs |
Cancer |
Melanoma, Hematological Cancer, Colorectal Cancer |
1NRP |
|
ONR-001
Therapeutic area:
Cancer
|
 |
Oryzon |
Vafidemstat (ORY-2001) - CNS optimized LSD1 inhibitor |
Biodrugs/ Drugs |
Central Nervous System |
Borderline Personality Disorder (BPD)
Clinical Trial "PORTICO" - recruiting
Interim Analysis 4Q22 |
4PhII |
|
Vafidemstat (ORY-2001) - CNS optimized LSD1 inhibitor
Therapeutic area:
Central Nervous System
|
|
Oryzon |
Vafidemstat (ORY-2001) - CNS optimized LSD1 inhibitor |
Biodrugs/ Drugs |
Central Nervous System |
Kabuki Syndrome
Clinical Trial "HOPE" - in preparation
IND 1H22 / FPI 1H22 |
4PhII |
|
Vafidemstat (ORY-2001) - CNS optimized LSD1 inhibitor
Therapeutic area:
Central Nervous System
|
|
Oryzon |
Vafidemstat (ORY-2001) - CNS optimized LSD1 inhibitor |
Biodrugs/ Drugs |
Central Nervous System |
Schizophrenia (Negative Symptoms & Cognition)
Clinical Trial "EVOLUTION" - recruiting |
4PhII |
|
Vafidemstat (ORY-2001) - CNS optimized LSD1 inhibitor
Therapeutic area:
Central Nervous System
|
|
Oryzon |
Vafidemstat (ORY-2001) - CNS optimized LSD1 inhibitor |
Biodrugs/ Drugs |
Central Nervous System |
SetD1A Compass related SCZ
New Clinical Trial - Under study |
4PhII |
|
Vafidemstat (ORY-2001) - CNS optimized LSD1 inhibitor
Therapeutic area:
Central Nervous System
|
|
Oryzon |
Iadademstat (ORY-1001) - Selective LSD1 inhibitor |
Biodrugs/ Drugs |
Cancer |
AML - 1L Elderly / Unfit
Clinical Trial "ALICE" (Combo w azacitidine)
Ongoing - fully enrolled
2H22 EHA/ASH Final Data |
4PhII |
|
Iadademstat (ORY-1001) - Selective LSD1 inhibitor
Therapeutic area:
Cancer
|
|
Oryzon |
Iadademstat (ORY-1001) - Selective LSD1 inhibitor |
Biodrugs/ Drugs |
Cancer |
ED-SCLC 1L
Clinical Trial "STELLAR" (Combo with ICI)
In preparation
IND 1H22 7 FPI 2H22 |
4PhII |
|
Iadademstat (ORY-1001) - Selective LSD1 inhibitor
Therapeutic area:
Cancer
|
|
Oryzon |
Iadademstat (ORY-1001) - Selective LSD1 inhibitor |
Biodrugs/ Drugs |
Cancer |
AML - R/R-Flt3 mut+
Clinical Trial "FRIDA" (combo w gilteritinib)
IND approved
FPI 1H22 |
3PhI |
|
Iadademstat (ORY-1001) - Selective LSD1 inhibitor
Therapeutic area:
Cancer
|
|
Oryzon |
Selective HDAC-6i |
Biodrugs/ Drugs |
Others |
Undisclosed |
2RP |
|
Selective HDAC-6i
Therapeutic area:
Others
|
|
Oryzon |
Iadademstat (ORY-1001) - Selective LSD1 inhibitor |
Biodrugs/ Drugs |
Cancer |
NETs R/R
Clinical Trial "NET Basket" (Combo w other agents)
In preparation
IND 1H22 / FPI 2H22 |
4PhII |
|
Iadademstat (ORY-1001) - Selective LSD1 inhibitor
Therapeutic area:
Cancer
|
|
Oryzon |
Other selective LSD1i |
Biodrugs/ Drugs |
Others |
Non-Oncological |
2RP |
|
Other selective LSD1i
Therapeutic area:
Others
|
 |
PaloBiofarma |
PBF-509 |
Biodrugs/ Drugs |
Cancer
Central Nervous System |
Lung Cancer |
4PhII |
Spain |
PBF-509
Therapeutic area:
Cancer
Central Nervous System
|
|
PaloBiofarma |
PBF680 |
Biodrugs/ Drugs |
Respiratory and Pulmonary system |
Asthma |
4PhII |
Spain |
PBF680
Therapeutic area:
Respiratory and Pulmonary system
|
|
PaloBiofarma |
PBF-999 |
Biodrugs/ Drugs |
Cancer |
Solid Tumors |
3PhI |
Spain |
PBF-999
Therapeutic area:
Cancer
|
 |
Peaches Biotech |
PRS SCARBOOST |
Biodrugs/ Drugs |
Others |
Advanced cell therapy drug with adult mesenchymal and fibroblast stem cells and fibroblast PRS for surgical scar treatment |
2RP |
|
PRS SCARBOOST
Therapeutic area:
Others
|
|
Peaches Biotech |
OPT CELL |
Biodrugs/ Drugs |
Cancer |
Pancreas cancer treatment and other solid cancer |
2RP |
|
OPT CELL
Therapeutic area:
Cancer
|
|
Peaches Biotech |
PRS CK STORM |
Biodrugs/ Drugs |
Autoimmune & Inflammation
Infections |
Cytoquine storm in COVID-19, pancreatis and sepsis |
2RP |
|
PRS CK STORM
Therapeutic area:
Autoimmune & Inflammation
Infections
|
|
Peaches Biotech |
PRS NEUROPAINBOOST |
Biodrugs/ Drugs |
Analgesia & Pain |
Neuropathic pain treatment |
2RP |
|
PRS NEUROPAINBOOST
Therapeutic area:
Analgesia & Pain
|
|
Peaches Biotech |
PRS MIOBOOST |
Biodrugs/ Drugs |
Musculoskeletal Disorders |
Muscle tissue regeneration |
2RP |
|
PRS MIOBOOST
Therapeutic area:
Musculoskeletal Disorders
|
|
Peaches Biotech |
PRS TENOBOOST |
Biodrugs/ Drugs |
Musculoskeletal Disorders |
Tendon regeneration |
2RP |
|
PRS TENOBOOST
Therapeutic area:
Musculoskeletal Disorders
|
|
Peaches Biotech |
PRS OSTEOBOOST |
Biodrugs/ Drugs |
Musculoskeletal Disorders |
Bone regeneration |
2RP |
|
PRS OSTEOBOOST
Therapeutic area:
Musculoskeletal Disorders
|
 |
Peptomyc |
OMO-103 |
Biodrugs/ Drugs |
Cancer |
First pan-MYC inhibitor in the clinic |
3PhI |
Spain |
OMO-103
Therapeutic area:
Cancer
|
 |
PharmaMar |
ZEPZELCA (lurbinectedin) + Irinotecan |
Biodrugs/ Drugs |
Cancer |
Small cell lung cancer 2nd line |
4PhII |
|
ZEPZELCA (lurbinectedin) + Irinotecan
Therapeutic area:
Cancer
|
|
PharmaMar |
ZEPZELCA (lurbinectedin) + IO |
Biodrugs/ Drugs |
Cancer |
Mesothelioma >= 2nd line |
5PhIII |
|
ZEPZELCA (lurbinectedin) + IO
Therapeutic area:
Cancer
|
|
PharmaMar |
PM54 |
Biodrugs/ Drugs |
Cancer |
Solid tumors |
3PhI |
|
PM54
Therapeutic area:
Cancer
|
|
PharmaMar |
PM14 (ecubectedin) combination trials |
Biodrugs/ Drugs |
Cancer |
Solid tumors |
3PhI |
|
PM14 (ecubectedin) combination trials
Therapeutic area:
Cancer
|
|
PharmaMar |
ZEPZELCA (Lurbinectedin) + Irinotecan/Topotecan |
Biodrugs/ Drugs |
Cancer |
Small cell lung cancer 2nd line |
5PhIII |
Europe and USA |
ZEPZELCA (Lurbinectedin) + Irinotecan/Topotecan
Therapeutic area:
Cancer
|
|
PharmaMar |
PM534 |
Biodrugs/ Drugs |
Cancer |
Solid tumors |
3PhI |
|
PM534
Therapeutic area:
Cancer
|
|
PharmaMar |
ZEPZELCA (lurbinectedin) + Atezolizumab |
Biodrugs/ Drugs |
Cancer |
Small cell lung cancer 2nd line IST Combos |
4PhII |
|
ZEPZELCA (lurbinectedin) + Atezolizumab
Therapeutic area:
Cancer
|
|
PharmaMar |
PM14 (ecubectedin) |
Biodrugs/ Drugs |
Cancer |
Solid tumors (basket trial) |
4PhII |
Europe and USA |
PM14 (ecubectedin)
Therapeutic area:
Cancer
|
|
PharmaMar |
PM14 (ecubectedin) combination radiation |
Biodrugs/ Drugs |
Cancer |
Soft tissue sarcoma |
3PhI |
|
PM14 (ecubectedin) combination radiation
Therapeutic area:
Cancer
|
|
PharmaMar |
PM14 (ecubectedin) |
Biodrugs/ Drugs |
Cancer |
Prostate cancer |
3PhI |
|
PM14 (ecubectedin)
Therapeutic area:
Cancer
|
|
PharmaMar |
ZEPZELCA (lurbinectedin) + Atezolizumab |
Biodrugs/ Drugs |
Cancer |
Small cell lung cancer Maintenance |
5PhIII |
|
ZEPZELCA (lurbinectedin) + Atezolizumab
Therapeutic area:
Cancer
|
 |
REIG JOFRE |
P0265 |
Biodrugs/ Drugs |
Dermatology |
Skin infections |
5PhIII |
Spain, Mexico |
P0265
Therapeutic area:
Dermatology
|
|
REIG JOFRE |
P0223 |
Biodrugs/ Drugs |
Dermatology |
Skin infection |
6Reg. |
Spain |
P0223
Therapeutic area:
Dermatology
|
 |
Sanifit |
SNF472 |
Biodrugs/ Drugs |
Cardiovascular and circulatory systems
Metabolic / Endocrinology |
Calciphylaxis |
5PhIII |
|
SNF472
Therapeutic area:
Cardiovascular and circulatory systems
Metabolic / Endocrinology
|
|
Sanifit |
SNF472 |
Biodrugs/ Drugs |
Cardiovascular and circulatory systems
Metabolic / Endocrinology |
Peripheral Arterial Disease (dialysis) |
5PhIII |
|
SNF472
Therapeutic area:
Cardiovascular and circulatory systems
Metabolic / Endocrinology
|
 |
SOM Biotech |
SOM0061 |
Biodrugs/ Drugs |
Infections
Respiratory and Pulmonary system |
COVID-19 |
4PhII |
|
SOM0061
Therapeutic area:
Infections
Respiratory and Pulmonary system
|
|
SOM Biotech |
SOM0044 |
Biodrugs/ Drugs |
Central Nervous System
Genetic Diseases and Dysmorphic syndromes |
Confidential |
2RP |
|
SOM0044
Therapeutic area:
Central Nervous System
Genetic Diseases and Dysmorphic syndromes
|
|
SOM Biotech |
SOM0208 |
Biodrugs/ Drugs |
Central Nervous System
Genetic Diseases and Dysmorphic syndromes
Metabolic / Endocrinology |
Confidential |
2RP |
|
SOM0208
Therapeutic area:
Central Nervous System
Genetic Diseases and Dysmorphic syndromes
Metabolic / Endocrinology
|
|
SOM Biotech |
SOM0034 |
Biodrugs/ Drugs |
Central Nervous System
Genetic Diseases and Dysmorphic syndromes
Musculoskeletal Disorders |
Confidential |
2RP |
|
SOM0034
Therapeutic area:
Central Nervous System
Genetic Diseases and Dysmorphic syndromes
Musculoskeletal Disorders
|
|
SOM Biotech |
SOM0045 |
Biodrugs/ Drugs |
Central Nervous System
Genetic Diseases and Dysmorphic syndromes |
Confidential |
2RP |
|
SOM0045
Therapeutic area:
Central Nervous System
Genetic Diseases and Dysmorphic syndromes
|
|
SOM Biotech |
SOM1311 |
Biodrugs/ Drugs |
Central Nervous System
Genetic Diseases and Dysmorphic syndromes
Metabolic / Endocrinology |
Phenylketonuria |
4PhII |
Phase 2a: EU |
SOM1311
Therapeutic area:
Central Nervous System
Genetic Diseases and Dysmorphic syndromes
Metabolic / Endocrinology
|
|
SOM Biotech |
SOM3366 |
Biodrugs/ Drugs |
Central Nervous System
Genetic Diseases and Dysmorphic syndromes
Musculoskeletal Disorders |
Tardive Dyskinesia |
3PhI |
Phase 1: EU |
SOM3366
Therapeutic area:
Central Nervous System
Genetic Diseases and Dysmorphic syndromes
Musculoskeletal Disorders
|
|
SOM Biotech |
SOM3355 |
Biodrugs/ Drugs |
Central Nervous System
Genetic Diseases and Dysmorphic syndromes |
Chorea in Huntington's disease |
4PhII |
Phase IIb: EU |
SOM3355
Therapeutic area:
Central Nervous System
Genetic Diseases and Dysmorphic syndromes
|
 |
Sylentis |
Tivanisirán (SYL1001) |
Biodrugs/ Drugs |
Ophthalmology and optometry |
Dry eye disease |
5PhIII |
|
Tivanisirán (SYL1001)
Therapeutic area:
Ophthalmology and optometry
|
|
Sylentis |
SYL1801 |
Biodrugs/ Drugs |
Ophthalmology and optometry |
Macular degeneration |
4PhII |
|
SYL1801
Therapeutic area:
Ophthalmology and optometry
|
 |
THERIVA BIOLOGICS |
VCN-01 |
Gene / Cell Therapy |
Cancer |
In combination with CAR-T cells for mesothelin positive tumors (ovarian/ pancreatic) |
3PhI |
USA |
VCN-01
Therapeutic area:
Cancer
|
|
THERIVA BIOLOGICS |
VCN-01 |
Gene / Cell Therapy |
Cancer
Central Nervous System |
High-grade brain tumours |
3PhI |
UK |
VCN-01
Therapeutic area:
Cancer
Central Nervous System
|
|
THERIVA BIOLOGICS |
VCN-01 |
Gene / Cell Therapy |
Cancer |
Head & Neck Cancer |
3PhI |
Spain |
VCN-01
Therapeutic area:
Cancer
|
|
THERIVA BIOLOGICS |
VCN-01 |
Gene / Cell Therapy |
Cancer |
Pancreatic cancer |
4PhII |
Spain, Germany, USA |
VCN-01
Therapeutic area:
Cancer
|
|
THERIVA BIOLOGICS |
VCN-11 |
Gene / Cell Therapy |
Cancer |
Solid Tumors |
2RP |
|
VCN-11
Therapeutic area:
Cancer
|
|
THERIVA BIOLOGICS |
VCN-02 |
Gene / Cell Therapy |
Cancer |
Solid Tumors |
1NRP |
|
VCN-02
Therapeutic area:
Cancer
|
|
THERIVA BIOLOGICS |
VCN-01 |
Gene / Cell Therapy |
Cancer |
Retinoblastoma |
3PhI |
Spain |
VCN-01
Therapeutic area:
Cancer
|
 |
Vivia Biotech |
Vivia 009 |
Biodrugs/ Drugs |
Blood and Lymphatic systems
Central Nervous System |
Non Hodgkin Lymphoma, CNS |
2RP |
Europe |
Vivia 009
Therapeutic area:
Blood and Lymphatic systems
Central Nervous System
|
|
Vivia Biotech |
Vivia 011 |
Biodrugs/ Drugs |
Metabolic / Endocrinology |
Obesity, Diabetes |
1NRP |
|
Vivia 011
Therapeutic area:
Metabolic / Endocrinology
|
 |
ZENDAL |
MTBVAC |
Vaccines |
Infections
Respiratory and Pulmonary system |
A uniquely attenuated M. tuberculosis strain, MTBVAC, was generated by genetically engineering two independent unmarked stable deletion mutations in the virulence genes PhoP and fadD26.
The Spanish vaccine manufacturer CZVaccines S.A./BIOFABRI, S.L.U. pr |
5PhIII |
|
MTBVAC
Therapeutic area:
Infections
Respiratory and Pulmonary system
|